Back to homepage

 

HEMLIBRA is a MEDSAFE registered prescription medicine.

Roche is working closely with all relevant stakeholders to achieve the earliest possible funding for all people with haemophilia A.

 

Current funding application time-line for HEMLIBRA in people with haemophilia A with non-inhibitors.

xmlns="http://www.w3.org/2000/svg">

Hemlibra received a high priority recommendation from Pharmac’s PTAC August 2021

xmlns="http://www.w3.org/2000/svg">

Hemlibra reviewed by Pharmac’s Haematology Subcommittee November 2021

xmlns="http://www.w3.org/2000/svg">

Roche is having ongoing discussions with Pharmac June 2022

PTAC = Pharmacology and Therapeutics Advisory Committee


back to homepage

Link to Third Party Site

You are about to leave the site to one that is not controlled or developed by Roche Products (New Zealand) Ltd.

Roche does not endorse or control the content of any linked websites and if you click OK, you agree that Roche has no responsibility or duty to you for anything that happens to you as a result. If the linked site is outside New Zealand’s jurisdiction, the information may not be consistent with New Zealand’s legislation, advertising codes or the relevant New Zealand registered Data Sheet. Please refer to the Data Sheet or Consumer Medicine Information on the Medsafe website for product information applicable to New Zealand.

Click OK to continue.

Cancel OK